Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02089347 |
|
Recruitment Status :
Completed
First Posted : March 17, 2014
Results First Posted : October 8, 2015
Last Update Posted : May 30, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The aim of the study is to generate additional safety and immunogenicity data to support the registration of the product in Japan.
Primary objectives:
- To demonstrate the non-inferiority of SP306 versus DT (DT 0.1mL) vaccine in terms of diphtheria and tetanus booster response rate (proportion of subjects with booster responses) and seroprotection rate (percentage of subjects with antitoxin concentrations ≥0.1 IU/mL) at 28 days (window 28-35 days) after one injection in Japanese adolescents 11-12 years of age.
- To evaluate the immune response of SP306 against the pertussis antigens PT and FHA in terms of booster response rate (proportion of subjects with booster responses) at 28 days (window 28-35 days) after one injection in Japanese adolescents 11-12 years of age.
Secondary objectives:
- To further evaluate the immune response of the study vaccines against diphtheria, tetanus and pertussis antigens.
- To assess the safety of the study vaccines after one injection in Japanese adolescents 11-12 years of age.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tetanus Diphtheria Pertussis | Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed Biological: Diphtheria and Tetanus toxoids adsorbed | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 534 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) Given Intramuscularly Compared to Diphtheria and Tetanus Toxoids Adsorbed (DT) Given Subcutaneously in Japanese Adolescents 11 - 12 Years of Age |
| Study Start Date : | March 2014 |
| Actual Primary Completion Date : | September 2014 |
| Actual Study Completion Date : | March 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SP306 Group
Participants randomized to receive SP306 vaccine intramuscularly
|
Biological: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
0.5 mL, intramuscularly.
Other Names:
|
|
Active Comparator: DT Group
Participants randomized to receive DT vaccine subcutaneously
|
Biological: Diphtheria and Tetanus toxoids adsorbed
0.1 mL, Subcutaneously
Other Name: DT vaccine |
- Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT [ Time Frame: Day 28 post-vaccination ]
Diphtheria booster response was defined as a ≥4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration ≤ 2.56 IU/mL or a ≥ 2-fold rise in a subject with a pre-vaccination antitoxin concentration >2.56 IU/mL. A tetanus booster response is defined as a ≥ 4-fold rise in pre- to post-vaccination antitoxin concentration in a subject with a pre-vaccination antitoxin concentration ≤ 2.7 IU/mL or a ≥ 2-fold rise in a subject with a pre-vaccination antitoxin concentration >2.7 IU/mL.
Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method
- Percentage of Participants With Seroprotection to Diphtheria and Tetanus Antigens Post-booster Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 28 post-vaccination ]
Seroprotection was defined as the proportion of subjects at 28 days post-vaccination with diphtheria and tetanus antitoxin concentration ≥0.1 IU/mL.
Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method
- Percentage of Participants With Pertussis Booster Response Following Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 28 post-vaccination ]
Pertussis booster response was defined as a pre-vaccination antibody concentration less than the lower limit of quantitation (LLOQ) and a post vaccination level ≥ 4XLLOQ; or a pre-vaccination antibody concentration ≥ LLOQ but < 4XLLOQ and a 4-fold rise (i.e. post/pre-vaccination ≥ 4); or a pre-vaccination antibody concentrations ≥ 4XLLOQ and a 2-fold rise (i.e. post/pre-vaccination ≥2).
Pertussis antitoxin concentration were assayed by the enzyme-linked immunosorbent assay (ELISA) method.
- Percentage of Participation With Seroprotection to Diphtheria and Tetanus Antigens Before Vaccination With Either SP306 or DT Vaccine [ Time Frame: Pre-vaccination (Day 0) ]
Seroprotection was defined as the proportion of participants with pre-vaccination with diphtheria and tetanus antitoxin concentration ≥ 0.1 IU/mL.
Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method.
- Percentage of Participants With Seroprotection to Diphtheria and Tetanus Antigens Before and Following Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 0 (pre-vaccination) and Day 28 post-vaccination ]
Seroprotection was defined as the proportion of participants with diphtheria and tetanus antitoxin concentration level ≥ 0.01 IU/mL.
Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method.
- Geometric Mean Concentration of Diphtheria and Tetanus Antibodies Before and Following Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 0 (pre-vaccination) and Day 28 post-vaccination ]Diphtheria antitoxin concentration was assayed by the toxin neutralization test; Tetanus antitoxin concentration was assayed by the enzyme-linked immunosorbent assay (ELISA) method
- Percentage of Participants With Pertussis (Pertactin and Fimbriae Types 2 and 3) Booster Response Following Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 28 post-vaccination ]
Pertussis booster response was defined as a pre-vaccination antibody concentration less than the lower limit of quantitation (LLOQ) and a post-vaccination level ≥ 4XLLOQ; or a pre-vaccination antibody concentration ≥ LLOQ but < 4XLLOQ and a 4-fold rise (i.e. post/pre-vaccination ≥ 4); or a pre-vaccination antibody concentrations ≥ 4XLLOQ and a 2-fold rise (i.e. post/pre-vaccination ≥2).
Pertussis antitoxin concentration were assayed by the enzyme-linked immunosorbent assay (ELISA) method.
- Geometric Mean Concentration of Pertussis Antibodies Before and Following Vaccination With Either SP306 or DT Vaccine [ Time Frame: Day 0 (pre-vaccination) and Day 28 post-vaccination ]Pertussis antitoxin concentration were assayed by the enzyme-linked immunosorbent assay (ELISA) method
- Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following a Single Booster Dose of SP306 or DT Vaccine [ Time Frame: Day 0 up to Day 7 post-vaccination ]Solicited injection-site: Pain, Erythema, Swelling; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 injection-site: Pain Significant, prevents daily activity; Erythema and Swelling >100 mm. Grade 3 systemic reactions: Fever, >39˚C; Headache, Malaise, and Myalgia, Significant, prevents daily activity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 11 Years to 12 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 11 or 12 years and considered healthy on the day of inclusion
- Informed consent form and assent form signed and dated by the parent(s) / legal representative(s) and the subject respectively
- Completed childhood vaccination against diphtheria, pertussis and tetanus (i.e., received 4 doses of Japanese-produced DTaP vaccine), confirmed by checking immunization records and have not yet undergone additional DT vaccination
- Able to attend all scheduled visits and to comply with all trial procedures
- For female subjects, either pre-menarchal, or post-menarchal with a negative urine pregnancy test.
Exclusion Criteria:
- Any conditions or diseases which, in the opinion of the Investigator:
- would pose a health risk to the subject
- or might interfere with the ability to participate fully in the study
- or might interfere with evaluation of the vaccine
- or would otherwise make participation inappropriate according to the Investigator's clinical judgment
- History of diphtheria, tetanus, pertussis, confirmed either clinically, serologically, or microbiologically
- Suspected or known hypersensitivity to any of the vaccine components or history of a life threatening reaction to a vaccine containing the same substances of the study vaccine
- Vaccination in the last 5 years against tetanus, diphtheria, and/or pertussis
- Known or suspected congenital immunodeficiency, or current / previous acquired immunodeficiency, or current / previous receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, or current / previous (within the last 6 months) systemic corticosteroid therapy
- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial inclusion
- Planned participation in another clinical trial during the present trial period
- Receipt of blood or blood-derived products in the past 3 months, that might interfere with assessment of the immune response
- Receipt of any vaccine within the 4 weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least 2 weeks before the study vaccine
- Planned receipt of any vaccine during the trial period
- Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection
- At high risk for diphtheria, tetanus or pertussis infection during the trial
- Known pregnancy, or a positive urine pregnancy test
- Currently breastfeeding a child
- Known thrombocytopenia or history of thrombocytopenia
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion
- History of acute disseminated encephalomyelitis, encephalopathy, Guillain-Barré Syndrome (GBS), or autoimmune disease
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
- Identified as an employee of an Investigator, a study center, a study-affiliated vendor, or the Sponsor, with direct or indirect involvement in the proposed study or other studies under the direction of that Investigator or study center; or identified as a spouse or child (whether natural or adopted) of such an employee.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089347
| Japan | |
| Aichi, Japan, 451 8511 | |
| Chiba, Japan, 299 4503 | |
| Fukui, Japan, 910 0833 | |
| Fukui, Japan, 918 8205 | |
| Gunma, Japan, 372 0817 | |
| Hyogo, Japan, 655 0017 | |
| Ibaraki, Japan, 312 0057 | |
| Kagoshima, Japan, 890 0034 | |
| Kanagawa, Japan, 223 0051 | |
| Nagano, Japan, 381 0025 | |
| Okayama, Japan, 701 0205 | |
| Okayama, Japan, 712 8064 | |
| Osaka, Japan, 574 0046 | |
| Shizuoka, Japan, 420 8623 | |
| Shizuoka, Japan, 426 0067 | |
| Tokyo, Japan, 146 0023 | |
| Tokyo, Japan, 146 0095 | |
| Tokyo, Japan, 167 0052 | |
| Tokyo, Japan, 183 0042 | |
| Study Director: | Medical Director | Sanofi Pasteur Inc. |
| Responsible Party: | Sanofi Pasteur, a Sanofi Company |
| ClinicalTrials.gov Identifier: | NCT02089347 |
| Other Study ID Numbers: |
Td536 (EFC12579) U1111-1124-7550 ( Other Identifier: WHO ) |
| First Posted: | March 17, 2014 Key Record Dates |
| Results First Posted: | October 8, 2015 |
| Last Update Posted: | May 30, 2017 |
| Last Verified: | April 2017 |
|
Tetanus Diphtheria Pertussis TdaP vaccine DT vaccine |
|
Whooping Cough Tetanus Diphtheria Tetany Bordetella Infections Gram-Negative Bacterial Infections Bacterial Infections Respiratory Tract Infections Infection Respiratory Tract Diseases Clostridium Infections Gram-Positive Bacterial Infections |
Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Hypocalcemia Calcium Metabolism Disorders Metabolic Diseases Corynebacterium Infections Actinomycetales Infections Vaccines Immunologic Factors Physiological Effects of Drugs |